Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNP-mRNA therapeutic for hearing loss
- Development stage
- Preclinical
- Lead developer
- CamGene Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratympanic, Intracochlear
01
Overview
LNP-mRNA therapeutics for hearing loss represent a novel class of genetic medicines designed to restore auditory function by delivering messenger RNA (mRNA) directly to the inner ear. These therapies utilize lipid nanoparticles (LNPs) to encapsulate and protect the mRNA, facilitating its delivery across the blood-labyrinth barrier and into target cells within the cochlea, such as hair cells or spiral ganglion neurons. Once internalized, the mRNA is translated into therapeutic proteins, such as brain-derived neurotrophic factor (BDNF) or other growth factors, which promote cellular regeneration, reduce inflammation, and prevent the degeneration of spiral ganglion neurons. This approach is primarily targeted at sensorineural hearing loss, a condition often characterized by the irreversible loss of these delicate auditory structures. CamGene Therapeutics is a prominent developer in this field, focusing on LNP-mediated delivery via the round window membrane to achieve localized and efficient protein expression.
- Other names
- LNP-mRNA hearing loss therapyLNP-BDNF mRNA
02
Targets
BDNF (Brain-derived neurotrophic factor)
Beyond the preview
Go deeper on LNP-mRNA therapeutic for hearing loss.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNP-mRNA therapeutic for hearing loss.